Carnosine And Anti-Ageing
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Subscribe to the distribution list, to get regular updates on supplement research for health,
🧠 NeuroBright Our evidence-based brain supplement formulated from 1.7M research papers
What if one of the most prescribed drugs in the world — sitting in the medicine cabinets of millions of people over 50 — has been quietly protecting your brain all along? Or what if, as some patients have long suspected, it’s been doing the opposite? The statins-and-memory debate has been simmering for over a decade, ever since the US Food and Drug Administration added a warning label to these cholesterol-lowering medications in 2012, alerting patients to possible cognitive side effects [6]. That warning sent shockwaves through cardiology clinics and kitchen tables alike. Suddenly, people who had been faithfully taking their atorvastatin or simvastatin every morning began to wonder: is this pill protecting my heart at the expense of my mind?
The honest answer, after years of research and now over 7 million patients studied, is more interesting — and considerably more reassuring — than either side of the argument tends to admit. To help cut through the noise, VitacuityAI analysed 1.7 million research papers and selected the most relevant studies on this topic. Here is what the evidence actually shows.
To understand why this debate exists, you first need to understand what statins do — and why the brain is caught in the crossfire.
Statins work by blocking an enzyme called HMG-CoA reductase, which the body uses to manufacture cholesterol. They are extraordinarily effective at reducing LDL (“bad”) cholesterol in the blood and are the cornerstone of cardiovascular disease prevention. But here is where it gets complicated: cholesterol is not simply a villain. Your brain is, in fact, the most cholesterol-rich organ in your body, and it relies on cholesterol to build and maintain neurons, form synapses, and support the myelin sheaths that insulate nerve fibres. So when you reduce cholesterol throughout the body, the question naturally arises — does that affect the brain too? [5]
The answer is: it depends on the statin. Some statins, like simvastatin and lovastatin, are “lipophilic” — they dissolve in fat and can cross the blood-brain barrier relatively easily. Others, like rosuvastatin and pravastatin, are “hydrophilic” — they stay largely in the bloodstream and have limited access to the brain. This distinction has been central to the debate, with researchers wondering whether brain-penetrating statins might have meaningfully different cognitive effects than those that stay out [1].
But statins do more than just lower cholesterol. They also have anti-inflammatory effects, improve the health of blood vessel walls, and may reduce the accumulation of the amyloid plaques associated with Alzheimer’s disease. These properties have led researchers to ask whether statins might actually *protect* the ageing brain against dementia — particularly the kind caused by damaged blood vessels [1][5]. As with most things in brain science, the picture turned out to be far more nuanced than the original warning label suggested.
Evidence grade: Promising to Strong — multiple large studies and meta-analyses, though primarily observational
Let’s start with the headline finding — because it is considerably more reassuring than many people realise.
A 2021 systematic review published in the *Journal of the American College of Lipidology* examined 24 studies involving an extraordinary 1,404,459 participants aged 60 and over [6]. It included three randomised controlled trials (RCTs) — the gold standard of medical evidence — with follow-up periods ranging from 3.2 to 5.6 years. All three RCTs showed no significant association between statin use and adverse cognitive effects. In one, the odds ratio for cognitive impairment was 1.03 (95% CI: 0.82–1.30) — essentially, statin users had no more cognitive risk than non-users. Another showed an odds ratio of 1.0 (95% CI: 0.61–1.65). The mean difference in Mini-Mental State Examination (MMSE) scores was a clinically insignificant 0.06 points [6].
Among the 21 observational studies in the same review, 10 actually showed a *reduced* incidence of dementia in statin users, seven showed no association, and three showed cognitive decline progressing at a similar rate in both groups. Not one study in the entire review found statistically significant evidence that statins *increased* the risk of cognitive decline in people aged 60 and over [6].
The conclusion from this enormous body of data: the 2012 FDA warning, while appropriately cautious at the time, does not appear to be supported by the weight of controlled evidence.
Evidence grade: Promising — large observational data, but RCT confirmation still needed
Two recent meta-analyses have pooled the evidence and arrived at a broadly consistent and encouraging conclusion: statin users appear to have a meaningfully lower risk of developing dementia.
A 2025 systematic review and meta-analysis published in a peer-reviewed journal analysed 55 observational studies covering more than 7 million patients [3]. The headline finding: statin use was associated with a 14% reduction in dementia risk overall (hazard ratio 0.86; 95% CI: 0.82–0.91). The researchers also conducted subgroup analyses by gender, statin type, and diabetes status — and the protective association held across most subgroups [3].
A second 2025 meta-analysis drew on 34 observational studies and found that continuous use of statins for one year or more was significantly more protective than shorter-term use — suggesting that the brain benefits, if real, accrue over time rather than appearing immediately [4]. Intriguingly, this analysis also found that the protective effect appeared stronger in people carrying the ApoE ε4 allele — the most significant genetic risk factor for Alzheimer’s disease. Statin users with this gene variant appeared to derive greater dementia risk reduction than those without it [4].
A 2024 community cohort study from Beijing (the BABRI study) added granular detail to this picture, finding that sustained statin users among dyslipidemia patients showed better performance across multiple cognitive domains — overall cognition, memory, visuospatial ability, attention, executive function, and language — compared to untreated individuals [14]. The benefits were most pronounced in those aged 65 and over. In middle-aged participants, only attention showed a statistically significant improvement [14].
It is important to stress that these are *observational* studies, not controlled trials. This means we cannot rule out confounding factors — for example, people who take statins consistently may also have better access to healthcare, more monitoring of cardiovascular risk, and healthier overall habits. But the consistency of the signal across tens of millions of data points is difficult to dismiss.
Evidence grade: Promising — biological rationale is strong, but human trial data is limited
Vascular dementia — the second most common form of dementia after Alzheimer’s, caused by reduced blood flow to the brain — may be where statins have their clearest potential benefit.
A 2025 review examined the mechanistic role of statins in vascular dementia and found multiple plausible pathways [1]. Statins reduce atherosclerosis (the hardening and narrowing of arteries), lower inflammation in blood vessel walls, and may help reduce cerebral amyloid angiopathy — a condition where amyloid protein deposits in the brain’s blood vessels, triggering strokes and contributing to both vascular dementia and Alzheimer’s disease [1][8].
The logic is straightforward: if you protect the brain’s blood supply, you protect the brain. A 2012 secondary analysis of the Ginkgo Evaluation of Memory (GEM) study found that lipid-lowering medications, and statins in particular, were associated with delayed cognitive decline and dementia onset — both in participants who already had mild cognitive impairment at baseline and in those who did not [7].
A 2025 review also examined whether treating dyslipidemia *earlier in life* might offer protection against late-life cognitive dysfunction [5]. The hypothesis here is compelling: cardiovascular damage to the brain accumulates over decades, so addressing cholesterol levels in midlife — not just in old age — may be where the real protective window lies. This is an area of active investigation, but it aligns with the broader principle that brain health is built (or eroded) over a lifetime, not just in the final years [5].
Evidence grade: Conflicted — results vary depending on dementia stage, statin type, and individual patient factors
Here is where the story becomes more nuanced — and more honest.
When researchers look not at preventing dementia but at slowing its progression once established, the results are decidedly more mixed.
A 2023 longitudinal cohort study using the Swedish Registry for Cognitive/Dementia Disorders followed 15,586 patients with Alzheimer’s or mixed dementia (mean age 79.5 years) [9]. It found a modest dose-response effect: patients taking one defined daily dose of statins on average had 0.63 more MMSE points after three years compared to non-users (95% CI: 0.33–0.94). Simvastatin users fared slightly better than atorvastatin users (+1.01 MMSE points after three years, 95% CI: 0.06–1.97), and better than rosuvastatin users (+1.03 MMSE points, 95% CI: 0.26–1.80). These are small but statistically significant differences in a very large dataset [9].
However, a 2023 study drawing on data from the NILVAD trial took a different view. In 510 older adults with mild-to-moderate Alzheimer’s disease (average age 72.9 years, 34.9% statin users), ongoing statin use was *not* associated with any slowdown in cognitive decline over 18 months, measured on both the ADAS-Cog and the Clinical Dementia Rating Scale (β: -0.67; 95% CI: -1.71 to 0.36; p = 0.20) [12]. On the positive side, statin use was also not associated with any increase in adverse events, falls, or liver problems [12].
A small but directly relevant 2021 trial of simvastatin in 31 patients with vascular dementia (20 receiving 80mg simvastatin daily, 11 receiving placebo, over 12 weeks) found that while LDL was reduced by 54% and total cholesterol by 48%, there was no measurable improvement in cognitive function versus the placebo group [10]. The study was small and short — 12 weeks is unlikely to be sufficient to demonstrate cognitive change — but it serves as a useful caution against over-optimism.
The overall picture for established dementia: statins appear safe to continue, and may offer marginal cognitive benefit for some patients, particularly in the earlier stages — but they are not a treatment for dementia once it has taken hold.
Evidence grade: Early stage — genuinely interesting signal, but small samples and needs replication
One of the most intriguing — and least-discussed — findings in this field is that statins may have fundamentally different effects depending on your genetic makeup and sex.
A 2020 study from the Banner Alzheimer’s Institute in Arizona examined verbal learning and memory in cognitively unimpaired adults aged 47–75 with a family history of Alzheimer’s disease [15]. The findings were striking in their complexity. In APOE4 *non-carriers*, statin use was associated with *better* verbal learning — but in APOE4 *carriers*, statin use appeared to have no benefit, and in women with the APOE4 gene, it was associated with *worse* performance on verbal learning and memory tasks [15].
Similarly, higher LDL cholesterol was associated with worse verbal memory in APOE4 non-carriers — but had no clear effect in APOE4 carriers [15].
What does this mean in plain English? It suggests that the relationship between cholesterol, statins, and cognition is not one-size-fits-all. Your genetic risk profile for Alzheimer’s disease may substantially determine whether statins help or are neutral — and possibly, in specific subgroups (particularly women carrying the APOE4 gene), whether they carry any cognitive cost.
This is a relatively small study and should not be over-interpreted. But it raises important questions about personalised medicine — the idea that the right decision about statins may ultimately depend not just on your cardiovascular risk, but on your genetic makeup [15].
The 2025 meta-analysis that found greater dementia protection in ApoE ε4 carriers [4] points in a different direction — adding to the complexity rather than resolving it. These two findings are not necessarily contradictory (one concerns prevention, one concerns cognitive performance in currently unimpaired individuals), but they highlight how much we still have to learn about gene-drug interactions in this area.
This is the most important section of any honest piece of writing about statins and the brain — because there is a great deal we do not yet know, and it matters.
The RCT gap is real. Almost all of the large-scale evidence suggesting that statins protect against dementia comes from observational studies [3][4][6]. These are invaluable for identifying patterns across millions of people, but they cannot prove causation. People who take statins consistently tend to have more health-conscious lifestyles, more regular medical check-ups, and better management of other cardiovascular risk factors. It is possible that some of the apparent cognitive benefit attributed to statins is actually a reflection of better overall health management. We need large, long-term randomised controlled trials specifically designed to test cognitive outcomes — and so far, those trials either don’t exist or have followed participants for too short a time [6][12].
The timing question is unresolved. Does it matter *when* you start statins? The suggestion from one 2025 review that treating dyslipidemia earlier in life may be more protective than starting in old age [5] is biologically plausible but not yet confirmed in rigorous trials. If there is a protective window — a period in midlife when statin use might meaningfully reduce your future dementia risk — we don’t yet know precisely when it opens or closes.
The which-statin question remains open. Lipophilic statins (simvastatin, lovastatin) cross the blood-brain barrier; hydrophilic statins (rosuvastatin, pravastatin) largely do not. Several studies suggest that simvastatin may have modestly different cognitive effects compared to atorvastatin or rosuvastatin [9]. But whether this difference is beneficial, harmful, or clinically irrelevant at typical doses remains genuinely unclear [1][9].
The individual variability problem. The APOE4 findings remind us that average population effects may conceal meaningfully different outcomes in specific subgroups [15][4]. A drug that is broadly safe and possibly beneficial for the population at large might have different implications for someone with the APOE4 gene, or for women at genetic risk for Alzheimer’s. This is not a reason for alarm — but it is a reason for better personalised medicine and, ideally, more research in specific genetic subgroups.
The CoQ10 question. One study examined whether statins might deplete CoQ10 — a compound involved in cellular energy production — and whether this could affect cognitive function [11]. The study followed 1,573 subjects over 5–10 years using multiple cognitive tests and found no significant cognitive effects for either statin use or CoQ10 levels [11]. But the question of whether CoQ10 supplementation in statin users offers any benefit remains insufficiently studied.
Short study durations. Several of the available trials followed participants for months rather than years. Dementia develops over decades. A 12-week or even 18-month study may simply be too short to detect meaningful cognitive effects — in either direction [10][12].
If you are taking statins for cardiovascular protection and you are worried about your memory — here is what the evidence actually says.
You almost certainly do not need to stop taking your statins because of memory concerns. Three randomised controlled trials and dozens of observational studies covering over a million participants have found no credible evidence that statin use increases the risk of cognitive impairment in people over 60 [6]. The FDA’s 2012 warning, while responsible at the time given the case reports that prompted it, has not been supported by the large-scale controlled data gathered since. The biggest meta-analysis to date — 55 studies, over 7 million patients — suggests statins may actually reduce your risk of developing dementia by around 14% [3].
If you have been avoiding statins partly because of memory fears, it is worth revisiting that decision with your doctor. The cardiovascular benefits of statins are well-established and substantial. The fear that they harm the brain appears, on current evidence, to be largely unfounded.
The most promising story here is about prevention, not treatment. Statins appear to have their greatest potential cognitive benefit when used earlier — protecting blood vessels and reducing inflammation in the brain before significant damage has occurred [5][7]. Once dementia is established, the evidence for statins slowing its progression is weak and inconsistent [10][12]. Think of statins less as a brain treatment and more as part of a long-term strategy to keep your cardiovascular system — and therefore your brain — in better shape as you age.
If you carry the APOE4 gene and are taking statins, this is genuinely worth discussing with a neurologist or specialist, not because the evidence shows harm, but because the interaction between genetic risk, cholesterol, and statin use appears to be complex and not yet fully understood [15][4]. This is one area where “talk to your doctor” is genuinely the right answer rather than a cop-out.
For everyone else: the practical, sensible position — based on the totality of evidence reviewed here — is that continuing your prescribed statin is almost certainly the right decision for both heart and brain. Look after your sleep, exercise regularly, manage stress, and eat well alongside it. No single drug does all the work. But the evidence suggests that statins, far from being the memory-robbers some feared, are more likely to be quiet allies in the long game of healthy ageing.
[1] Statins for vascular dementia: A hype or hope (2025). https://pubmed.ncbi.nlm.nih.gov/39746645/
[2] Neuro-cognitive profile of adult statin users at a large tertiary care hospital in Delhi, India (2025). DOI: 10.1177/20480040251371770 | https://pubmed.ncbi.nlm.nih.gov/40917489/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409027/
[3] Statin use and dementia risk: A systematic review and updated meta-analysis (2025). https://pubmed.ncbi.nlm.nih.gov/39822593/
[4] Statins and the risk of dementia: a meta-analysis (2025). https://pubmed.ncbi.nlm.nih.gov/40199829/
[5] Lipid Lowering Agents and Late Life Cognitive Dysfunction (2025). https://pubmed.ncbi.nlm.nih.gov/40377326/
[6] Association between statin use and cognitive function: A systematic review of randomized clinical trials and observational studies (2021). DOI: 10.1016/j.jacl.2020.10.007 | https://pubmed.ncbi.nlm.nih.gov/33189626/
[7] Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study (2012). https://pubmed.ncbi.nlm.nih.gov/21236699/
[8] Statins for vascular dementia: A hype or hope (2025). https://pubmed.ncbi.nlm.nih.gov/39746645/
[9] Statins and cognitive decline in patients with Alzheimer’s and mixed dementia: a longitudinal registry-based cohort study (2023). DOI: 10.1186/s13195-023-01360-0 | https://pubmed.ncbi.nlm.nih.gov/38115091/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10731754/
[10] Action of simvastatin in improving cognitive functions in vascular dementia (2021). https://pubmed.ncbi.nlm.nih.gov/34103439/
[11] Statins, Enzyme CoQ10, and Cognitive Function (2022). DOI: 10.1177/08919887211044747 | https://pubmed.ncbi.nlm.nih.gov/34493115/
[12] What is the impact of ongoing statin use on cognitive decline and dementia progression in older adults with mild-moderate Alzheimer disease? (2023). DOI: 10.1371/journal.pone.0285529 | https://pubmed.ncbi.nlm.nih.gov/37167234/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174559/
[13] Neuro-cognitive profile of adult statin users at a large tertiary care hospital in Delhi, India (2025). DOI: 10.1177/20480040251371770 | https://pubmed.ncbi.nlm.nih.gov/40917489/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409027/
[14] Cognitive function in dyslipidemia patients: exploring the impact of statins (2024). DOI: 10.3389/fneur.2024.1436010 | https://pubmed.ncbi.nlm.nih.gov/39350969/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439768/
[15] Effects of LDL Cholesterol and Statin Use on Verbal Learning and Memory in Older Adults at Genetic Risk for Alzheimer’s Disease (2020). DOI: 10.3233/JAD-191090 | https://pubmed.ncbi.nlm.nih.gov/32390619/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Quick Read CoQ10 is a molecule found in your cells’ power stations (mitochondria) that helps convert food into energy your
